PT-141 (Bremelanotide) vs Thymosin Alpha-1
Updated July 29, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of PT-141 (Bremelanotide) and Thymosin Alpha-1 (also searched as Thymosin Alpha-1 vs PT-141 (Bremelanotide)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
PT-141 (Bremelanotide) centers on neuro, while Thymosin Alpha-1 leans toward healing. On indexed research, Thymosin Alpha-1 is ahead (PT-141 (Bremelanotide): 13 studies, Human evidence; Thymosin Alpha-1: 16, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •PT-141 (Bremelanotide) is strongest for neuro; Thymosin Alpha-1 for healing.
- •Evidence: PT-141 (Bremelanotide) Human evidence (13 studies) vs Thymosin Alpha-1 Human clinical (16).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Melanocortin agonist | Sexual dysfunction
Synthetic Thymic Hormone | Immune System Modulator
PT-141 (Bremelanotide) vs Thymosin Alpha-1: side-by-side
| Metric | PT-141 (Bremelanotide) | Thymosin Alpha-1 |
|---|---|---|
| Class | Healing | Immune |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 13 | 16 |
| Research level | FDA Approved | Well Studied |
| Strongest effect | Neuro & mood | Healing & recovery |
| Healing & recovery | 0.0 | 4.0▲ |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 0.0 |
| Neuro & mood | 4.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 1.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | PT-141 (Bremelanotide) | Thymosin Alpha-1 |
|---|---|---|
| Mechanism | Melanocortin receptor agonist | Enhances T-cell function and promotes maturation of immune cells |
| Route | Subcutaneous injection | — |
| Half-life | ~2.7 hours | — |
| Time to peak | 1 hour | — |
| Duration of action | Up to 24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is PT-141 (Bremelanotide)?
### Summary PT-141 (Bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, primarily investigated for its potential to treat sexual dysfunction, particularly in women experiencing hypoactive sexual desire disorder. Its mechanism of action involves the modulation of pathways related to sexual arousal and desire.
Full PT-141 (Bremelanotide) profile, mechanism & studies →What is Thymosin Alpha-1?
### Thymosin Alpha-1 Summary Thymosin Alpha-1 (Tα1) is a peptide that plays a crucial role in modulating immune responses and has been investigated for its potential therapeutic applications in various conditions, including infections and inflammatory diseases.
Full Thymosin Alpha-1 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Thymosin Alpha-1 | 4.0/5 effect signal |
| Neuro | PT-141 (Bremelanotide) | 4.0/5 effect signal |
| Inflammation | Thymosin Alpha-1 | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack PT-141 (Bremelanotide) and Thymosin Alpha-1?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
PT-141 (Bremelanotide) vs Thymosin Alpha-1: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
PT-141 (Bremelanotide) has 13 approved studies indexed (Human evidence), and Thymosin Alpha-1 has 16 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is PT-141 (Bremelanotide) or Thymosin Alpha-1 better?
It depends on your goal. PT-141 (Bremelanotide) is strongest for neuro; Thymosin Alpha-1 for healing. Thymosin Alpha-1 has more indexed studies (16). See the goal-by-goal breakdown above.
Which has more research, PT-141 (Bremelanotide) or Thymosin Alpha-1?
PT-141 (Bremelanotide) has 13 approved studies indexed (Human evidence); Thymosin Alpha-1 has 16 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack PT-141 (Bremelanotide) and Thymosin Alpha-1?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of PT-141 (Bremelanotide) vs Thymosin Alpha-1?
PT-141 (Bremelanotide): no community-reported effects logged yet. Thymosin Alpha-1: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is PT-141 (Bremelanotide) or Thymosin Alpha-1 FDA-approved?
PT-141 (Bremelanotide) is FDA-approved. Thymosin Alpha-1 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Thymosin Alpha-1 better than PT-141 (Bremelanotide)?
For healing, Thymosin Alpha-1 has the edge; for neuro, PT-141 (Bremelanotide) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 29, 2026.